{"url_path":"/sec/nvct/8-k/2026-06-23/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-076624-index.html","accession_number":"0001104659-26-076624","cik":"0001875558","ticker":"NVCT","issuer_name":"Nuvectis Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-076624-index.html","primary_entity_key":"0001875558","primary_entity_name":"Nuvectis Pharma, Inc."},"word_count":96,"has_tables":true,"body_markdown":"**Item 9.01.**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\nThe following exhibit is filed herewith:\n\n \n\n**Exhibit**\n \n \n\n**Number**\n \n**Description**\n\n[99.1](tm2618439d1_ex99-1.htm)\n \n[Press release issued by Nuvectis Pharma, Inc., dated June 22, 2026.](tm2618439d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\n \n**Nuvectis Pharma, Inc.**\n\n \n(Registrant)\n\n \n \n \n\nDate: June 23, 2026\n \n \n\n \nBy:\n/s/ Ron Bentsur\n\n \n \nRon Bentsur\n\n \n \nChairman, Chief Executive Officer and President"}